Cellular apoptotic pathways converge on the activation of procaspase-3, resulting in the production of active caspase-3. Caspase-3 catalyzes the hydrolysis of hundreds of cellular substrates and, once activated, rapidly induces apoptotic cell death. In 2006 we reported PAC-1 as the first small molecule to directly activate procaspase-3, and since then we have defined the mechanism by which this compound activates procaspase-3, and have synthesized hundreds of derivatives. Given that procaspase-3 levels are elevated in many tumor tissues, PAC-1 and related compounds have considerable potential for treatment of cancer. Toward this end, PAC-1 and its derivative S-PAC-1 have been evaluated in canine cancer patients, and PAC-1 is now being administered to human cancer patients through a Phase I clinical trial at the University of Illinois Cancer Center in Chicago and at Johns Hopkins University. See more information at clinicaltrials.gov.
Related Publications:
- The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma
Boudreau MW, Tonogai EJ, Schane CP, Xi MX, Fischer JH, Vijayakumar J, Ji Y, Tarasow TM, Fan TM, Hergenrother PJ, Dudek AZ
Melanoma Res. 2023, in press published on web September 22, 2023
Link to journal
- Phase 1 dose escalation study of procaspase activating compound-1 (PAC-1) in combination with temozolomide in patients with recurrent high-grade astrocytomas
Holdhoff M, Nicholas KM, Peterson RA, Maraka S, Liu LC, Fischer JH, Wefel JS, Fan TM, Vannorsdall T, Russell M, Iacoboni M, Tarasow TM, Hergenrother PJ, Dudek AZ, Danciu OC Neuro-Oncol. Adv. 2023, published on web July 19, 2023
Link to journal
- Phase 1 study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies
Danciu OC, Holdhoff M, Peterson RA, Fisher JH, Liu LC, Wang H, Venepalli NK, Chowdhery R, Nicholas MK, Russell MJ, Fan TM, Hergenrother PJ, Tarasow TM, Dudek AZ
Brit. J. Cancer 2023, 128, 783
Link to journal
Article PDF
- Evaluation of a procaspase-3 activator with hydroxyureas or temozolomide against high-grade meningioma in cell culture and canine cancer patients
Tonogai, E.; Huang, S.; Botham, R.; Berry, M.; Joslyn, S.; Daniel, G.; Chen, Z.; Rao, J.; Zhang, X.; Basuli, F.; Rossmisl, J.; Riggins, G.; LeBlanc, A.; Fan, T.; Hergenrother, P.J.
Neuro-Oncology 2021, 23, 1723-1735.
Link to journal
Article PDF
- Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential
Boudreau, M. W.; Peh, J.; Hergenrother, P. J.
ACS Chem. Biol. 2019, 14, 2335-2348.
Link to journal
Article PDF
- Immunohistochemical characterization of procaspase-3 overexpression as a druggable target with PAC-1, a procaspase-3 activator, in canine and human brain cancers
Schlein, L. J.; Fadl-Alla, B.; Pondenis, H. C.; Lezmi, S.; Eberhart, C. G.; LeBlanc, A. K.; Dickinson, P. J.; Hergenrother, P. J.; Fan, T. M.
Front. Oncol. 2019, 9, 96
Link to journal
Article PDF
- Overcoming resistance to targeted anticancer therapies through small-molecule mediated MEK degradation
Peh, J.; Boudreau, M. W.; Smith, H. M.; and Hergenrother, P. J.
Cell Chem. Biol. 2018, 25, 996-1005.
Link to journal
Article PDF
- Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients
Joshi, A. D.; Botham, R. C.; Schlein, L. J.; Roth, H. S.; Mangraviti, A.; Borodovsky, A.; Tyler, B.; Joslyn, S.; Looper, J. S.; Podell, M.; Fan, T. F.; Hergenrother, P. J.;
Riggins, G. J.
Oncotarget 2017, 8, 80124-80138.
Link to journal
Article PDF
- Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics
Botham, R. C.; Roth, H. S.; Book, A. P.; Roady, P. J.; Fan, T. M.; Hergenrother, P. J.
ACS Central Science 2016, 2, 545-559.
Link to journal
Article PDF
- The Combination of Vemurafenib and Procaspase-3 Activation is Synergistic in Mutant BRAF Melanomas
Peh, J.; Fan, T. M.; Wycislo, K. L.; Roth, H. S.; Hergenrother, P. J.
Mol. Cancer Ther. 2016, 15, 1859-1869.
Link to journal
Article PDF
- Derivatives of Procaspase-Activating Compound 1 (PAC-1) and Their Anticancer Activities
Roth, H. S.; Hergenrother, P. J.
Curr. Med. Chem. 2016, 23, 201-241 (review).
Link to journal
Article PDF
- Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics
Roth, H. S.; Botham, R. C.; Schmid, S. C.; Fan, T. M.; Dirikolu, L.; Hergenrother, P. J.
J. Med. Chem. 2015, 58, 4046-4065.
Link to journal
Article PDF
- Dual Small-Molecule Targeting of Procaspase-3 Dramatically Enhances Zymogen Activation and Anticancer Activity
Botham, R. C.; Fan, T. M.; Im, I.; Borst, L. B.; Dirikolu, L.; Hergenrother, P. J.
J. Am. Chem. Soc. 2014, 136, 1312-1319.
Link to journal
Article PDF
- Differential effects of procaspase-3 activating compounds in the induction of cancer cell death
West, D. C.; Qin, Y.; Peterson, Q. P.; Thomas, D. L.; Palchaudhuri, R. P.; Morrison, K. C.; Lucas, P. W.; Palmer, A. E.; Fan, T. M; Hergenrother, P. J.
Mol. Pharmaceutics 2012, 9, 1425-1434.
Link to journal
Article PDF
- Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)
Hsu, D. C.; Roth, H. S.; West, D. C.; Botham, R. C.; Novotny, C. J.; Schmid, S. C.; Hergenrother, P. J.
ACS Comb. Sci. 2012, 14, 44-50.
Link to journal
Article PDF
- Pharmacokinetics and Derivation of an Anticancer Dosing Regimen for PAC-1, a Preferential Small Molecule Activator of Procaspase-3, in Healthy Dogs
Lucas, P. W.; Schmit, J. M.; Peterson, Q. P.; West, D. C.; Hsu, D. C.; Novotny, C. J.; Dirikoul, L.; Deorge, D. R.; Garrett, L. D.; Hergenrother, P. J.; Fan, T. M.
Invest. New Drugs 2011, 29, 901-911.
Link to journal
Article PDF
- Discovery and Canine Preclinical Assessment of a Nontoxic Procaspase-3-Activating Compound
Peterson, Q. P.; Hsu, D. C.; Novotny, C. J.; West, D. C.; Kim, D.; Schmit, J. M.; Dirikolu, L.; Hergenrother, P. J.; Fan, T. M.
Cancer Res. 2010, 70, 7232-7241.
Link to journal
Article PDF
UIUC News Highlight
WAND Video
- Preparation of the Caspase-3/-7 Substrate Ac-DEVD-pNA via Solution-Phase Peptide Synthesis
Peterson, Q. P.; Goode, D. R.; West, D. C.; Botham, R. C.; Hergenrother, P. J.
Nature Protocols 2010, 5, 294-302.
Link to journal
Article PDF
- Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of PAC-1, and its Cellular Co-Localization with Caspase-3
Peterson, Q. P.; Hsu, D. C.; Goode, D. R.; Novotny, C. J.; Totten, R. K.; Hergenrother, P. J.
J. Med. Chem. 2009, 52, 5721-5731.
Link to journal
Article PDF
- PAC-1 Activates Procaspase-3 in vitro Through Relief of Zinc-Mediated Inhibition
Peterson, Q. P.; Goode, D. R.; West, D. C.; Ramsey, K. N.; Lee, J. J.; Hergenrother, P. J.
J. Mol. Biol. 2009, 388, 144-158.
Link to journal
Article PDF
- Small-Molecule Activation of Procaspase-3 to Caspase-3 as a Personalized Anticancer Strategy
Putt, K. S.; Chen, G. W.; Pearson, J. M.; Sandhorst, J. S.; Hoagland, M. S.; Kwon, J.-T.; Hwang, S.-K.; Jin, H.; Churchwell, M. I.; Cho, M.-H.; Doerge, D. R.; Helferich, W. G.; Hergenrother, P. J.
Nat. Chem. Biol. 2006, 2, 543-50.
Link to journal
Article PDF
BBC News Highlight – #1 Most emailed story on website worldwide on Monday, August 28, 3:20 pm
Scientific American Highlight
Guardian Highlight
Nature Podcast – September 7, 2006; description of our work starts ~19 minutes in
Nature Chemical Biology News Highlight
Nature Reviews Research Highlight
Chemical & Engineering News Highlight